RxDoctor Payments Data

Richard Gluckman, MD

Neurology · San Pedro, CANPI 1336288943

Payments from drug & device makers

$4,841in general payments, 2019–2025

Across 278 payments — averaging $17.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Biogen$816
  • Novartis$618
  • Lilly USA, LLC$266
  • Lundbeck LLC$258
  • Teva Pharmaceuticals USA, Inc.$189
  • plus $1K from 24 others

What the payments were for

  • Speaking & faculty fees$240%
  • Food & beverage$4,817100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,841 in reported general payments places this provider in the 60th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$38,272
Medicare patients
60
Services billed
2,281

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab23$198,783
IngrezzaValbenazine Tosylate12$100,133
BotoxOnabotulinumtoxina17$17,972
Glatiramer Acetate12$16,637
Rivastigmine26$4,220
Gabapentin113$2,938
Ropinirole ErRopinirole Hcl11$2,879
Rasagiline Mesylate12$2,431
Carbamazepine27$2,241
Memantine Hcl61$1,944
Levetiracetam48$1,506
Carbidopa-LevodopaCarbidopa/Levodopa36$1,271
Propranolol Hcl ErPropranolol Hcl16$795
Donepezil Hcl43$504
Ascomp With CodeineCodeine/Butalbital/Asa/Caffein11$474

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$29$100,13312 claims
AbbVieBotox$1,676$17,97217 claims
Upsher-smith Laboratories LLCTopiramate$42$34519 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,996 neurology providers in California.

Other neurology in San Pedro

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →